26.13
-0.0595(-0.23%)
Currency In USD
| Previous Close | 26.19 |
| Open | 25.96 |
| Day High | 26.2 |
| Day Low | 25.44 |
| 52-Week High | 34.5 |
| 52-Week Low | 14.4 |
| Volume | 861,515 |
| Average Volume | 1.24M |
| Market Cap | 1.74B |
| PE | -8.68 |
| EPS | -3.01 |
| Moving Average 50 Days | 23.34 |
| Moving Average 200 Days | 21.94 |
| Change | -0.06 |
If you invested $1000 in Celldex Therapeutics, Inc. (CLDX) 10 years ago, it would be worth $165.28 as of September 30, 2025 at a share price of $26.131. Whereas If you bought $1000 worth of Celldex Therapeutics, Inc. (CLDX) shares 5 years ago, it would be worth $1,762 as of September 30, 2025 at a share price of $26.131.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
GlobeNewswire Inc.
Sep 17, 2025 9:11 AM GMT
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immun
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 09, 2025 1:01 PM GMT
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
GlobeNewswire Inc.
Aug 19, 2025 8:01 PM GMT
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a